{"description":"Intent-to-treat population: All participants who received at least 1 dose of study drug.","eventGroups":[{"description":"Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":10,"seriousNumAffected":5,"seriousNumAtRisk":10,"title":"Bevacizumab 5 mg/kg"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10}],"term":"General physical health deterioration"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Pyrexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Hypercalcaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Hyperglycaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Haemorrhage"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Hypertension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Humerus fracture"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10}],"term":"Headache"}]}